Previous close | 274.49 |
Open | 274.68 |
Bid | 275.39 x 13700 |
Ask | 276.00 x 21700 |
Day's range | 273.87 - 276.43 |
52-week range | 228.65 - 312.99 |
Volume | |
Avg. volume | 704,941 |
Market cap | 133.083B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 35.44 |
EPS (TTM) | 7.77 |
Earnings date | 13 Feb 2024 |
Forward dividend & yield | 3.81 (1.39%) |
Ex-dividend date | 11 Mar 2024 |
1y target est | 300.66 |
Applications for camp that offers free world-class AI education to help prepare students for latest tech evolution are now openPHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. With a custom and highly-relevant curriculum focused on teaching students about the latest developments in the world of AI and Generative AI, the c
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated testing concerning nitrosamine levels Exclusive licensing deal for Australia and New Zealand with CSL Seqirus; CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialization of neffy. ARS Pharmaceutical
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with p